Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Goldenwell Biotech (GWLL) FCF Margin (2021 - 2024)

Goldenwell Biotech filings provide 4 years of FCF Margin readings, the most recent being 16044.94% for Q4 2024.

  • On a quarterly basis, FCF Margin rose 2338186.0% to 16044.94% in Q4 2024 year-over-year; TTM through Sep 2025 was 18438.61%, a 4771229.0% increase, with the full-year FY2024 number at 88544.6%, down 8238159.0% from a year prior.
  • FCF Margin hit 16044.94% in Q4 2024 for Goldenwell Biotech, up from 34353.24% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 16044.94% in Q4 2024 to a low of 36688.92% in Q1 2022.
  • Median FCF Margin over the past 4 years was 4790.86% (2023), compared with a mean of 8189.74%.
  • Biggest five-year swings in FCF Margin: surged 3444412bps in 2023 and later crashed -2459019bps in 2024.
  • Goldenwell Biotech's FCF Margin stood at 394.8% in 2021, then skyrocketed by 109bps to 34.84% in 2022, then plummeted by -21158bps to 7336.92% in 2023, then surged by 319bps to 16044.94% in 2024.
  • The last three reported values for FCF Margin were 16044.94% (Q4 2024), 34353.24% (Q2 2024), and 7336.92% (Q4 2023) per Business Quant data.